हिंदी में पढ़ें

Aurobindo Pharma

Aurobindo Pharma unit gets first product approval from USFDA

Aurobindo Pharma unit gets first product approval from USFDA

Wed, Sep 11, 2024

The new injectable facility of Eugia Steriles, a subsidiary of Eugia Pharma Specialities and a stepdown unit of the company, situated at Anakapalli District of Andhra Pradesh was inspected by the US FDA from March 28 to April 5 this year.

Aurobindo Pharma arm gets warning letter from USFDA for formulations unit in Telangana

Aurobindo Pharma arm gets warning letter from USFDA for formulations unit in Telangana

Fri, Aug 16, 2024

Aurobindo Pharma Ltd's subsidiary Eugia Pharma Specialities Ltd has received a warning letter from the USFDA for its Telangana-based formulation manufacturing unit. This follows the unit's earlier classification as 'Official Action Indicated' (OAI). Despite this, the company assures there is no impact on current US market supplies and remains committed to improving compliance with FDA regulations.

Analyzing Aurobindo Pharma's Recent Action

Analyzing Aurobindo Pharma's Recent Action

Mon, Jul 15, 2024

Why is Aurobindo Pharma in action? Board meeting on July 18, big decision possible. Know complete details from Nupur.

TRENDING NOW

Stock of the Day : Today Anil Singhvi gave buying advice in Aurobindo Pharma Futures

Stock of the Day : Today Anil Singhvi gave buying advice in Aurobindo Pharma Futures

Mon, Jul 15, 2024

Stock of the Day; Today Anil Singhvi gave buying advice in Aurobindo Pharma Futures. What is stoploss and targets? See in this video.

This midcap pharma company gains over 2%,inches close to its 52-week high price: Check details

This midcap pharma company gains over 2%,inches close to its 52-week high price: Check details

Tue, May 28, 2024

Goldman Sachs is bullish on pharma stock and believes further margin expansion is on the cards post the strong Q4 show.

Post-Results Analysis: Which Stocks to Buy? Insights by Anil Singhvi

Post-Results Analysis: Which Stocks to Buy? Insights by Anil Singhvi

Mon, May 27, 2024

Results Review : Divi's Laboratories, Torrent Pharma, Aurobindo Pharma, Glenmark Pharma, United Spirits, Hindalco, Ashok Leyland और NTPC के नतीजे कैसे रहे? नतीजों के बाद किन शेयरों में करें खरीदारी? जानिए एनालिसिस Anil Singhvi से.

Dr Reddy's, Sun Pharma, Aurobindo recall products in US

Dr Reddy's, Sun Pharma, Aurobindo recall products in US

Sun, May 19, 2024

The USFDA said the drug maker initiated the Class I recall in the US on April 8 this year.

Aurobindo Pharma gets tax demand of over Rs 13 crore, including interest, penalty

Aurobindo Pharma gets tax demand of over Rs 13 crore, including interest, penalty

Fri, May 03, 2024

The Deputy Commissioner (ST) STU-1 of GST, Punjagutta Division, Hyderabad, Commercial Taxes Department, Telangana, has passed an order under relevant provisions of the Central Goods and Services Tax Act, 2017 and TGST Act 2017 for the FY 2018-19 to this effect.

Inside Aurobindo Pharma: Exploring the Force Behind its Dynamic Actions

Inside Aurobindo Pharma: Exploring the Force Behind its Dynamic Actions

Mon, Apr 01, 2024

Why strong action in Aurobindo Pharma? Commercial production begins at Muhar PenG plant - Zee Business news

Stock of the Day : Anil Singhvi gives buying opinion in Aurobindo Pharma

Stock of the Day : Anil Singhvi gives buying opinion in Aurobindo Pharma

Mon, Apr 01, 2024

Stock of the Day: Today Anil Singhvi gave buying opinion in Aurobindo Pharma.. What is the stoploss and targets? See in this video...

Aurobindo Pharma shares gain up to 4% on commissioning four state-of-the-art manufacturing facilities

Aurobindo Pharma shares gain up to 4% on commissioning four state-of-the-art manufacturing facilities

Mon, Apr 01, 2024

"Aurobindo Pharma Limited has commissioned four state-of-the-art manufacturing facilities for PenicillinG, 6-Amino Penicillanic Acid (6-APA), injectable products, and granulation through its wholly owned subsidiaries," said the company's filing.

Aurobindo Pharma shares gain after drug maker wins US regulator approval for nasal spray

Aurobindo Pharma shares gain after drug maker wins US regulator approval for nasal spray

Wed, Mar 20, 2024

Aurobindo Pharma share price: Aurobindo Pharma shares gained over two per cent to Rs 1,013.6 apiece on NSE, rising for the fifth session in a row, after the Hyderabad-headquartered drug maker received approval from the US FDA for its nasal spray. Aurobindo Pharma said the product would be launched in the first quarter of the fiscal year 2025.

Aurobindo Pharma soars nearly 5% after US FDA's nod to its Gilenya Capsules

Aurobindo Pharma soars nearly 5% after US FDA's nod to its Gilenya Capsules

Sat, Mar 02, 2024

"Aurobindo Pharma Limited is pleased to announce that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fingolimod Capsules, 0.5 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation. The product will be launched in March 2024," said Aurobindo Pharma in a statement on Friday.

Aaj Ke 2000: Why did Anil Singhvi give buy opinion in Aurobindo Pharma Foot?

Aaj Ke 2000: Why did Anil Singhvi give buy opinion in Aurobindo Pharma Foot?

Mon, Feb 19, 2024

'Today's 2000' Why did Anil Singhvi give a buy opinion on Aurobindo Pharma Foot? What are triggers, targets and stoploss? Know here

Aurobindo Pharma jumps higher after mixed December quarter results; here's what Macquarie says about it

Aurobindo Pharma jumps higher after mixed December quarter results; here's what Macquarie says about it

Mon, Feb 12, 2024

Aurobindo Pharma's consolidated profit after tax (PAT) skyrocketed by 91 per cent to Rs. 940 crore against Rs 491 crore Year-on-Year (YoY), compared to Zee Business research estimates of Rs. 904 crore. Its revenue from operations for the December quarter was up by 15 per cent to Rs 7352 crore in Q3 compared to 6407 crore YoY, below research estimates of Rs 7421 crore.

Aurobindo Pharma Q3 Results: Profit and revenue jump; announces interim dividend

Aurobindo Pharma Q3 Results: Profit and revenue jump; announces interim dividend

Sat, Feb 10, 2024

The board also approved an interim dividend of 150 per cent, i.e. INR 1.5 per equity share of INR 1/- for the year FY23-24.

Aurobindo Pharma Q3 Results Preview: Net profit likely to jump 84%, margin may expand by 600 bps

Aurobindo Pharma Q3 Results Preview: Net profit likely to jump 84%, margin may expand by 600 bps

Sat, Feb 10, 2024

Aurobindo Pharma is estimated to report a year-on-year jump of more than 84 per cent in consolidated net profit to Rs 904 crore for the October-December period, according to Zee Business research.

Aurobindo Pharma slips after US FDA issues 9 observations to Eugia Pharma

Aurobindo Pharma slips after US FDA issues 9 observations to Eugia Pharma

Mon, Feb 05, 2024

Aurobindo Pharma's subsidiary, Eugia Pharma's Unit III, had been issued nine observations from the US FDA. The investigation was conducted from January 22 to February 2.

Aurobindo Pharma gets boost despite US FDA raised objections in its American subsidiary's inspection

Aurobindo Pharma gets boost despite US FDA raised objections in its American subsidiary's inspection

Tue, Dec 26, 2023

"The United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection (PAI) at new injectable facility of Eugia US Manufacturing LLC (a step-down wholly owned subsidiary of Aurobindo Pharma Ltd.), situated at East Windsor, New Jersey, USA from December 11 to December 22, 2023," Aurobindo Pharma said in a statement on Sunday.

Aurobindo unit gets USFDA nod to market generic asthma medication

Aurobindo unit gets USFDA nod to market generic asthma medication

Thu, Nov 30, 2023

Eugia Pharma Specialities has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide Inhalation Suspension, the Hyderabad-based drug firm said in a regulatory filing.

Aurobindo Pharma gets USFDA approval for HIV drug

Aurobindo Pharma gets USFDA approval for HIV drug

Wed, Nov 29, 2023

The pharma company has received final approval from the USFDA, US Food and Drug Administration to manufacture and market 600 and 800 mg Darunavir tablets, said the Hyderabad-based drug maker.

Aurobindo Pharma stock hits a 52-week high for 3rd day in a row after its US subsidiary gets US FDA approval for Ryzneuta

Aurobindo Pharma stock hits a 52-week high for 3rd day in a row after its US subsidiary gets US FDA approval for Ryzneuta

Wed, Nov 22, 2023

Ryzneuta™ is the first non-pegylated granulocyte colony-stimulating factor approved by both the US Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA) for treatment for chemotherapy-induced neutropenia, Aurobindo Pharma said in a statement.

US drug regulator completes inspection at Aurobindo Pharma subsidiary's Telangana facility; shares clock 52-week high

US drug regulator completes inspection at Aurobindo Pharma subsidiary's Telangana facility; shares clock 52-week high

Mon, Nov 20, 2023

The FDA classified the findings of the inspection as 'no action indicated', which which means no objectionable conditions or practices were found during the inspection.

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x